Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,155 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

NCT01594320
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

NCT00944073
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

NCT01320696
View directory record Official record
Conditions
Influenza
Interventions
Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

NCT01310413
View directory record Official record
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus monovalent vaccine, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
11
States / cities
Paramount, California • Sacramento, California • Newton, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational

QuickVue Influenza A + B Test Field Study

NCT03417869
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
QuickVue Influenza A+B
Device
Lead sponsor
Quidel Corporation
Industry
Eligibility
Not listed
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, New York • Belton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

NCT00735475
View directory record Official record
Conditions
Influenza
Interventions
CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
13
States / cities
Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 10, 2026, 9:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

NCT05832307
View directory record Official record
Conditions
Influenza
Interventions
Existing Influenza Vaccination Practices, Standardized inpatient influenza vaccination program
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 99 Years
Enrollment
22,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

NCT03581903
View directory record Official record
Conditions
Influenza
Interventions
H7N3 pLAIV, H7N9 pIIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nasal Swab Home Collection Kit (NSHC Kit) Study

NCT03813966
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Sofia Influenza A+B FIA
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years and older
Enrollment
1,181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Afluria Pregnancy Registry

NCT03442582
View directory record Official record
Conditions
Influenza, Human, Pregnancy, Birth Defect
Interventions
Afluria Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
Female only
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

NCT04785794
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Sing2016 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

NCT02957656
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Oseltamivir in Newborns and Infants

NCT01388439
View directory record Official record
Conditions
Prematurity of Fetus
Interventions
Oseltamivir
Drug
Lead sponsor
St. Louis Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1Phase 2 Interventional

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

NCT01728753
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Favipiravir
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 10, 2026, 9:28 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06476275
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Influenza A/Texas/71/2017 (H3N2), Sham placebo
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 46 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational Results available

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

NCT01467934
View directory record Official record
Conditions
Fever
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 23 Months
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 10, 2026, 9:28 PM EDT
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
View directory record Official record
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT04471038
View directory record Official record
Conditions
Influenza Type A, Influenza Type B, Influenza
Interventions
SAB-176, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

NCT05630365
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
Not listed
Enrollment
1,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 10, 2026, 9:28 PM EDT
Not listed Phase 2 Interventional

Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department

NCT00380679
View directory record Official record
Conditions
High Risk for Serious Influenza, High Risk for Pneumonia
Interventions
Influenza vaccination, Pneumococcal polysaccharide vaccination
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2006 · Synced Oct 10, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

NCT00885105
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 11 Months
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
6
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 10, 2026, 9:28 PM EDT